The CuMVTT-p33 vaccine formulated with MCT adjuvant enhanced the level of infiltrating of CD8+ and p33-specific CTLs into the tumor, and the production of IFN-γ in B16F10p33 melanoma model [191]. This evidence concerns the gene CD8A and melanoma.